Novo Nordisk's Next-Gen Weight-Loss Drug CagriSema Deemed 'Obsolete' After Disappointing Trial Results

Wegovy and Ozempic owner dealt blow as next-gen weight-loss drug is branded ‘obsolete’

Novo Nordisk’s shares fall sharply after testing of CagriSema falls short of investors’ expectations Business live – latest updates The owner of Wegovy and Ozempic has suffered a significant setback, as its highly anticipated new weight-loss treatment was labelled “obsolete” after disappointing clinical trials. Novo Nordisk’s shares fell sharply on Monday after the results from testing the Danish firm’s CagriSema drug fell short of investors’ expectations. Continue reading...

By Julia Kollewe